title: Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma.
abstract: Smoothened inhibitors represent the first class of targeted drugs approved for use in advanced and metastatic basal cell carcinoma. For many patients with limited treatment options, this drug class has led to significant clinical improvements, but is not without side effects. In this review, we outline the basic mechanism of smoothened inhibitors and the most commonly observed cutaneous and extracutaneous side effects. We also highlight possible mechanisms for these adverse events and current management strategies.
authors: Department of Dermatology, Stanford University School of Medicine, Redwood City, California.
authors: Shalini V
authors: SV
authors: Mohan
authors: Department of Dermatology, Stanford University School of Medicine, Redwood City, California. alschang@stanford.edu.
authors: Anne Lynn S
authors: AL
authors: Chang
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D002280:Basal Cell Carcinoma / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D019468:Disease Management; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors*; D012871:Skin Diseases / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D000072086:Smoothened Receptor
chemical_list: D000970:Antineoplastic Agents; D043562:Receptors, G-Protein-Coupled; C491023:SMO protein, human; D000072086:Smoothened Receptor